Utipro Plus/AF and the World Antimicrobial Awareness week
18-24 November 2022 we celebrate the World Antimicrobial Awareness Week 2022 (who.int)
World Antimicrobial Awareness Week (WAAW) is a global campaign that is celebrated annually to improve awareness and understanding of Anti-Microbial Resistance (AMR) and encourage best practices among the public, stakeholders and policymakers.
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become increasingly difficult or impossible to treat.
2022 theme of WAAW is “Preventing Antimicrobial Resistance Together” echoing the findings of a remarkable publication1 in The Lancet.
The study is the most comprehensive analysis of the burden of AMR to date, producing estimates for 204 countries and territories, 23 bacterial pathogens, and 88 pathogen–drug combinations, in 2019. Obtained data cover 471 million individual records or isolates, leading to the estimation of 1.27 million deaths attributable to bacterial AMR. Lower respiratory infections, bloodstream infections, intra-abdominal infections, urinary tract infections and tuberculosis accounted for most deaths attributed to AMR, being the six leading pathogens: Escherichia coli, followed by Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. This study provides the first comprehensive assessment of the global burden of AMR defined as a leading cause of death around the world, with the highest burdens in low-resource settings. Understanding the burden of AMR and the leading pathogen–drug combinations contributing to it is crucial to making informed and location-specific policy decisions, particularly about infection prevention and control programmes, access to essential antibiotics, and research and development of new vaccines and antibiotics1.
At Noventure we are concerned about AMR and with our product Utipro® Plus/Utipro® Plus AF, mentioned in the Guidelines of the Swiss Society of Gynaecology and Obstetrics (SSGO) among the antibiotic-free approaches for the treatment of acute and recurrent uncomplicated UTIs2, we would like to give maximum relevance to the European Association of Urology Guidelines on Urological Infections, which recommend antimicrobial stewardship programs in the management of the disease with the aim of optimizing clinical results and minimize unintended consequences of antimicrobial use3.
1 Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0
2 Betschart C. et al., Guideline of the Swiss Society of Gynaecology and Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy. Swiss Med Wkly. 2020;150:w20236 Open access online version www.smw.ch
3 Bonkat G. et al. EAU Guidelines on Urological Infections. Available online: https://uroweb.org/guideline/urological-infections
Utipro® Plus and Utipro® Plus AF are medical devices intended for the control and prevention of uncomplicated urinary tract infections and comply with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (Utipro® Plus CE 0373, Noventure SL - Utipro® Plus AF CE 0476, Noventure SL)
This information is only intended for Healthcare Professionals.
